HER2 Negative Breast Cancers
Jul 23, 2020
Olema raises $54M; T3 Pharma bags $27M to advance bacterial cancer therapy program; Biofourmis and Chugai’s Collaboration; A new study on averting heart attack
Olema Oncology raises USD 54 Million for breast cancer program Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&D efforts in other areas. The capital will bankroll a phase 1/2 study of the asset, OP-1250, as a single agent. Olema Oncology will a...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
